Recon: FDA approves Protagonist and Takeda’s drug for rare blood cancer; Lilly to buy Merida for up to $2.88B
Recon: FDA approves Protagonist and Takeda’s drug for rare blood cancer; Lilly to buy Merida for up to $2.88B RAPS
August 2026
Dr Mesa on the FDA Approval of Ropeginterferon Alfa-2b for Essential Thrombocythemia
Dr Mesa on the FDA Approval of Ropeginterferon Alfa-2b for Essential Thrombocythemia OncLive
FDA Approves Rusfertide for Polycythemia Vera
FDA Approves Rusfertide for Polycythemia Vera Medscape